Oscotec Inc.

Drug Discovery & Development

Oscotec Inc.

July 2020

Table of Contents

Disclaimer

This presentation has been prepared by Oscotec Inc.(the “Company”) solely for its own use at its presentation to company investors.

Information contained herein is strictly confidential, and is given only for your information and for your use and may not be copied, reproduced, distributed, redistributed or passed on, directly or indirectly, to any other person in any manner, or published, in whole or in part, for any purpose. Certain statements contained herein constitute forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. Words such as “anticipates,” “plans,” “estimates,” “expects” and variations of these words and similar expressions are intended to identify forward-looking statements. Such statements address future financial results and business standings.

Forward-looking statements are not guarantees of future performance and involve certain uncertainties and risks, which are affected by further changes in business environment. Therefore, actual future results and trends may differ materially from the forecasts reflected in the forward-looking statements herein due to a variety of factors including but not limited to the changes in market conditions and strategy revisions.

The Company is not liable for any investment decisions by its readers or subscribers and does not undertake any legal obligation to present any supporting evidence against investment results of investors under any circumstances.

Overview

About Oscotec Inc.

1-1. Overview

Oscotec Inc.

"R&D – Based Biotech Company for Drug Discovery and Development"

Profile

- Company : Oscotec Inc. (PanGyo, Gyeonggi-do, Korea)
- Establishment : Dec.8, 1998
- Listing : Jan.17, 2007 (KOSDAQ)
- Paid-in Capital : W15bn (Outstanding shares : 29,200,311)
- No. of Employees : 44 (R&D – 19)
- Subsidiary : Genosco (Boston, USA)

Area

- Autoimmune Disease
  - RA/ SLE/ ITP
- Cancer
  - AML/ NSCLC/ Breast cancer

History

- Dec. 2008 Establishment of US subsidiary (Boston Lab.)
- July 2015 L/O of EGFR-Targeted Anti-Cancer Drug (Oscotec→Yuhan)
- Sep. 2015 FDA Approval For SYK's Clinical Trial in US
- Apr. 2016 FDA Approval For FLT3's Clinical Trial in US
- Nov. 2018 L/O of EGFR-Targeted Anti-Cancer Drug (Yuhan→Janssen)

1-2. Key Personnel

Oscotec Inc.

James Kim Ph.D., D.D.S CEO

- Ph.D. in Biochemistry from Seoul National Univ.
- Dankook Univ. Prof.
- Harvard Medical School, Visiting Prof.

Tae-Young Yoon Ph.D. CEO

- Ph.D. in Organic Chemistry from Yale Univ.
- California Inst. of Technology, Post-Doc
- Novartis Pharma., Principal Scientist
- Dong-A ST Inc., SVP, Head of Research Center

Jung-Ho Kim Ph.D. CTO

- Ph.D. in Organic Chemistry from Univ. of Illinois at Urbana-Champaign
- Stanford Univ., Post-Doc
- Hanwha Chemical, Principal Scientist

Scott Lee MBA CFO

- Director/Management
- MBA in Business Administration from Dankook Univ.

Genosco Inc.

John Koh Ph.D. CEO

- Ph.D. in Bio-organic Chemistry California Institute of Technology
- KABIC President
- LG Life Science, R&D Head

Steve Kim Ph.D., D.D.S CTO

- Ph.D. in Pharmacology from Seoul National Univ.
- Dankook Univ. Prof.
- Harvard Medical School, Visiting Prof.

Kevin Yang B, Sc CFO

- Director/Management
- B. Sc in Communication from Seoul National Univ.

R&D Pipelines

1) ***Lazertinib (GNS-1480, YH25448)***
   : EGFR Mutant Inhibitor › *NSCLC*
2) ***SKI-O-703 : SYK Inhibitor*** › *RA, ITP*
3) ***SKI-G-801 : FLT Mutant Inhibitor*** › *AML*
4) ***SKI-G-801 : AXL Inhibitor*** › *Metastatic solid tumor (NSCLC, TNBC+)*

2. Kinase-Targeted Drug Discovery : Inhibitory Principle

Normal Kinase



Cancer-driving Kinase & Inhibitor



2. Focus on Selective Kinase Inhibitor

I. Kinase Selection



- One of 518 human Kinases
- High unmet needs for medicine
- Proven expertise in target selection

II. Discovery Engine



- Strong IP position
- Rational design
- *In silico docking* model

III. Company's Focused Chemical Library



- Novel proprietary compounds
- Structure-activity relationship
- Optimization

2. Drug Development Pipelines

Area	Product	Target	Discovery	Preclinical	Phase 1	Phase 2a	Phase 3	Developer
Immunology	**SKI-O-703**	SYK/RA						**OCT**
		SYK/ITP						
Oncology	**Lazertinib GNS-1480 (YH25448)**	EGFRdm+ / NSCLC						**YH/ Janssen**
		1st line NSCLC						
		1st line NSCLC (Combination)						
	SKI-G-801	FLT3m+/AML						**OCT**
		AXL/NSCLC, TNBC						

OCT, Oscotec Inc.

GNS, Genosco

YH, Yuhan. Pharmaceuticals

RA, Rheumatoid Arthritis; SLE, Systemic Lupus Erythematosus; ITP, Immune Thrombocytopenic Purpura;

AML, Acute Myeloid Leukemia; NSCLC, Non Small Cell Lung Cancer; EGFRdm+, EGFR double mutants

2-1. EGFR Mutant selective inhibitor

● **Indication**	NSCLC
● **Treatment Principle**	EGFR(del19/L858R)/T790M Double Mutant Inhibition
● **Market**	$6B (2023 Est.)
● **Efficacy**	Minimized Side Effects & Superior Efficacy
● **Clinical Study Status**	■ Single treatment 2nd Line: Phase 2 Completed ■ Combination treatment: Phase 3 (2020.2H~)
● **Remarks**	■ L/O : 2015.7 Oscotec → Yuhan, 2018.11 Yuhan → Janssen ∴ **60/40 Share for All Income** (Upfront US$50M + Milestone US$1.205B+ Running Royalty) ■ MFDS` Conditional Approval expected by 2020 & NDA filing for FDA Approval expected by 2023

Lazertinib

EGFR Double Mutant Inhibitor

2-1. Lazertinib : Summary efficacy & safety in clinical trials

Excellent Efficacy

Oral, once-a-day 20mg-320mg dose of Lazertinib

	Lazertinib (ASCO, 2019)	Osimertinib # (AURA trial)
Overall Response Rate	60% (n=127)	51% (n=253)
A T790M (+) Patient (All doses)	64%	61%
› T790M (+) Patient (120mg) *	65%	-
› T790M (+) Patient (80mg) **	-	70% (n=43)
› Progression Free Survival	12.3mos	10.1mos
B T790M (-) Patient (All doses)	37%	21%
C Patient with brain metastasis (All doses)	50%	N/A

Excellent Safety

One cycle of treatment: 21 days

	Lazertinib (ASCO, 2019)	Osimertinib # (AURA trial)
Any AEs of grade 3-5	11%	32%
Any drug related grade 3-5	3%	13%

Safety

No dose limiting toxicity (DLT) from starting dose of 20mg QD up to 320mg QD. Lazertinib showed no dose-dependently increased TEAEs whereas Osimertinib did dose-dependent adverse events of diarrhea(47%) and rash(40%) in AURA trial.

2-1. MET amplification

Key issue

- EGFR Mutant – Approx. 30% of NSCLC patient
- T790M Mutant – 45~50% of drug-resistant patient after 1st Line Treatment
- MET amplification – Approx. 30% of drug-resistant patient after 2nd line Treatment

Source : Chi-Med presentation.



Link

2-1. Combination effect with JNJ-6372 (EGFR/MET Ab)

An integrated EGFR pathway strategy to change the treatment paradigm

JNJ-6372
EGFRxcMET DuoBody®

A fully human, enhanced ADCC, bispecific antibody that targets EGFR and c-MET via novel MOA; currently being evaluated across the spectrum of EGFR and cMET altered tumors



Lazertinib YUHAN
3rd-generation EGFR inhibitor

A potent 3rd-generation EGFR TKI with highly favorable tolerability profile

Triple blockade of EGFR and cMET with JNJ-6372 and Lazertinib results in superior activity in preclinical model



In vivo preclinical activity: lung tumor xenograft driven by EGFR (T790M) and c-MET pathways; JNJ-6372 in combination with Lazertinib prevents tumor growth more effectively than either agent alone
DD18058; Eln: DuoBody-EGFR x cMet-00570

janssen | Pharmaceutical Companies of Johnson & Johnson

2-1. Janssen – 10 Pipelines over 1 Billion Potential

Our robust pipeline is anticipated to deliver at least 10 new medicines with >$1 billion potential*

Select NME approvals & filings in 2019–2023 timeframe

2019 approvals	Potential 2019–2023 filings	
Spravato™ (esketamine) CIII nasal spray Treatment-resistant depression	**JNJ-4550 cusatuzumab (Anti CD70 mAb)** Acute myeloid leukemia	**JNJ-7564 GPRC5D/CD3, JNJ-7957 BCMA/CD3** Regimens for multiple myeloma
	JNJ-4528 BCMA CAR-T Multiple myeloma	**JNJ-6372 EGFR/c-Met (Bispecific EGFR and cMET receptor inhibitor)** Solid tumor
Balversa™ (erdafitinib) tablets Urothelial cancer	**JNJ-1937 lazertinib (EGFR tyrosine-kinase inhibitor)** Non small cell lung cancer	**JNJ-4500 anti-NKG2D (anti-NKG2D mAb)** Crohn's disease
	AAV-CNGB3/CNGA3/RPGR (Gene Therapy) Retinal disease	**RSV Vaccine (Ad26.RSV.preF + preF Protein)** RSV
	niraparib (PARP inhibitor) Prostate cancer	**JNJ-7922 seltorexant (Orexin-2 receptor antagonist)** Adjunctive treatment, MDD

New since May, 2017

Accelerated since May, 2017

* Peak non-risk-adjusted sales, including partner sales

Note: Filings/approvals are in the US or EU, unless otherwise noted. This information is accurate as of the date hereof to the best of Johnson & Johnson's knowledge. The Company assumes no obligation to update this information

janssen | Pharmaceutical Companies of Johnson & Johnson

2-2. SKI-O-703 : SYK selective inhibitor

● **Indication**	Autoimmune Diseases - Rheumatoid Arthritis (RA), Immune Thrombocytopenia (ITP)..
● **Treatment Principle**	SYK Inhibitor → Block abnormal activation of immune cells
● **Market**	RA : $18.2B (2020), ITP : $520M (2020)
● **Efficacy**	Superior Efficacy & Safety
● **Clinical Study Status**	■ RA – Phase 2a (Apr. 2019~) ■ ITP – Phase 2a (Dec. 2019~)
● **Remarks**	■ Sponsored by KDDF ■ RA – L/O promotion from 4Q 2020.



SKI-O-703

SYK Inhibitor

2-2. SKI-O-703: Rat Rheumatoid Arthritis Model

Rheumatoid Arthritis

- Genetic evidence of SYK in RA



Jackus et al, 2010

Arthritis & Rheumatism 63: 1899-1910



B-cell, Mast cells, Macrophage, Dendritic cells, Neutrophil, Basophil Activation

- SYK deficient mouse : No sign of RA
- Novel mechanistic drug in RA market
- High potential to be first line therapy

Collagen Induced Arthritis (CIA) Rat Model



Rat CIA model: evaluation of clinical score

Note:

CP-690,550, Tofacitinib



2-2. SKI-O-703: Great Efficacy in Mouse ITP Model

Mouse ITP model

- Platelet count lowered by stimulation of aCD41 Antibody (2μg)

Day-1

- 9 am : collecting bleed & analyzing platelet count
- 1 pm : inhibitor oral dosing

Day 1

- 1 pm : inhibitor oral dosing
- 2 pm : aCD41 Ab, i.p. dosing

Day 2

- 1 pm : inhibitor oral dosing
- 2 pm : collecting bleed & analyzing platelet count



- Selective and potent inhibition of SKI-O-703: **Restore platelet level to normal**
- SKI-O-703 : More efficacious than R-788
- R788: NDA Approval for ITP (Apr., 2018)

*Two tailed Student *t-test* vs Vehicle group, * p<0.05, ** p<0.01, ***p<0.001

Two tailed Student *t-test* vs R788 group, # p<0.05,

2-2. Phase 1 Clinical Trial



- Healthy adult volunteer : 48 subjects
- **Safe and well tolerated by both healthy male and female subjects**
- **No significant findings in vital signs, ECG, and lab safety tests**
- Increased in a dose proportional manner (AUC and C^{max})

- Healthy adult volunteer : 24 subjects
- Dosing period : 7 days
- **Safe and well tolerated in all dose**
- **No significant findings in vital signs, ECG, and lab safety tests**
- Increased in a dose proportional manner (AUC and C^{max})

2-2. Timeline for clinical trials



I. Rheumatoid Arthritis (RA)

- RA with inadequate respose to csDMARDs or anti-TNFa biological agent(s)
- Dose : placebo, 100, 200, 400 mg (bid)
- Dosing period : 12 weeks
- 148 patients of 59 sites in 7 countries – US, EU, Korea
- FPI : April 2019

II. Immune Thrombocytopenia (ITP)

- ITP failed to respond or relapsed after at least 1 prior therapy
- Dose : placebo, 200, 400 mg (BID)
- Dosing period : 12 weeks
- 60 patients of 26 sites in 5 countries – US, EU, Korea
- FPI : December 2019

2-3. SKI-G-801 : FLT3 inhibitor

Indication	Acute Myeloid Leukemia
Treatment Principle	FLT3 Mutant Inhibition → Block FLT3 signal pathway and proliferation of blasts
Market	$1B (2020 Est.) : Demand expected to grow – Population aging, Progress in AML diagnostic, MKT entry of FLT3 inhibitors..
Efficacy	Superior FLT3 Mutant Inhibition & Efficacy in drug-resistant environments
Clinical Study Status	■ May 2018~ Phase 1 Dose Escalation Study ■ 1H 2021~ Phase 1 Efficacy Study (planned)
Remarks	■ Sponsored by MOHW ■ Published in the Blood journal (IF=9.8), 2014 ■ ODD Designated by FDA, November 2018

SKI-G-801

FLT3 Inhibitor

2-3. SKI-G801 : FLT3 Inhibitor for AML

Incidence of FLT3 mutations in AML

FLT3 mutants	Detail	Patients*
FLT3-ITD	20-30%	~8,400
FLT3-TKD D835Y	8-12%	~3,300

*, patient estimates represent new incidence in US

- > 65 AML patients: Low response and high relapse rate after first-line treatment (10% five-year survival rate)
- Occurrence of drug-resistant FLT3 mutants
  e.g. gatekeeper (F691L) & kinase domain mutant (D835Y)
- No treatment options for FLT3 double mutant (ITD/D835Y)
- High unmet needs of FLT3 inhibitor to apply for Induction and maintenance therapy



2-3. SKI-G801 : Drug-resistant FLT3 mutation

Potent anti-leukemic effect of drug-resistant FLT3 mutants

Compound	BaF3 cells with FLT3 mutation (IC_{50}, nM)			
	ITD	ITD/F691L	N676D	D835Y
G-749	8.0	38.3	20.4	3.4
AC220	1.1	858.5	14.2	73.8
ASP2215	16.0	163.6	25.4	4.1
PKC412	21.6	16.1	128.7	11.4

- G-749 (free base of SKI-G-801) potently inhibits proliferation of tested drug-resistant cells.

2-3. SKI-G-801: Persistent FLT3 inhibition

Persistent anti-leukemic activity



- After short incubation and wash-out, the inhibition of p-FLT3 is sustained by G-749 for 24 hours, whereas it is gradually reduced by AC220 or PKC412 in a time dependent manner.

Suppression of FLT3 downstream effectors



- Single SKI-G-801 (G-749 HCl salt) IV dosing at 7.5 mg/kg leads to complete inhibition of FLT3 downsteam effectors (p-STAT5 & p-ERK1/2) within 2 hours and their activities lasts for 24 hours.

2-4. SKI-G-801 : AXL inhibitor

Indication	Metastatic Solid Tumor (NSCLC, TNBC+)
Treatment Principle	AXL Inhibition → Inhibition of metastasis and recovery immune response (e.g. cytotoxic T cell activation) → Cancer cell extinction & suppression of drug-resistance
Market	>$1B (2025 Est.) : Applicable for broad range of cancers
Efficacy	Superior AXL inhibition and increased immune response
Clinical Study Status	4Q 2020 IND Filing → 1Q 2021 Phase 1 (planned)
Remarks	■ Presented at AACR (April 2019, June 2020) ■ Joint research with Prof. Cho Byeong-Chul (Yonsei University College of Medicine) ■ Strategy for combination therapy with IO Drugs

SKI-G-801

AXL Inhibitor (Immuno-Oncology)

2-4. SKI-G-801: AXL Target expansion for solid tumors

A CPI response vs AXL upregulation





B P-Axl inhibition (vs R428)



C Prolonged p-Axl inhibition (vs R428)



- AXL targeting would be highly beneficial to increase IO-drug's efficacy through blocking tumor immune escape
- Following GAS6 stimulation, SKI-G-801 inhibits p-AXL with a concentration-dependent manner in MDA-MD-231 cells, compared to R428
- The inhibition of p-Axl is sustained by G-749 for 8 hours, but the activity of R428 is gradually decreased

2-4. SKI-G-801: Suppression of Metastasis

Excellent in vivo Efficacy in Metastatic models

A Lung metastasis models (B16F10)



B Peritoneal metastasis models (CT-26)



2-4. SKI-G-801 : Immune cell-dependent anti-cancer effect

Anti-tumor effect dependent on immune response

B16F10 tumor



4T1 tumor



- There is no anti-tumor effect of SKI-G-801 in immunodeficient mice, indicating that SKI-G-801 may suppress tumor growth by directly engaging immune system

2-4. SKI-G-801: Combination effect with IO-drugs

A 4T1 spontaneous metastasis model



B Neoadjuvant therapy model



- The combination with SKI-G-801 and PD-1 shows greater inhibition of lung metastasis in the 4T1 spontaneous metastasis model (Figure A)
- Following neoadjuvant treatment for 6 days and tumor excision surgically, the combination-treated group increase overall survival rates in 4T1 syngeneic model (Figure B)

2-4. SKI-G-801: Combination effect with IO-drugs – PDX Model

The combination effect with SKI-G-801 and aPD-1 in Immuno-Avatars






Oct | Oscotec Inc.
Thank you!
www.oscotec.com